DDInter927 DDInter448
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Crizotinib {u} (Compound) treats {v} (Disease) lung cancer
Crizotinib {u} (Compound) binds {v} (Gene) MET
Crizotinib {u} (Compound) upregulates {v} (Gene) COL11A1
Crizotinib {u} (Compound) is included by {v} (Pharmacologic Class) Organic Cation Transporter 2 Inhibitors
Crizotinib {u} (Compound) downregulates {v} (Gene) WDR77
Crizotinib {u} (Compound) causes {v} (Side Effect) Dizziness postural
Crizotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Crizotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Crizotinib (Compound) treats lung cancer (Disease)
Crizotinib (Compound) binds MET (Gene)
Crizotinib (Compound) upregulates COL11A1 (Gene)
Crizotinib (Compound) is included by Organic Cation Transporter 2 Inhibitors (Pharmacologic Class)
Crizotinib (Compound) downregulates WDR77 (Gene)
Crizotinib (Compound) causes Dizziness postural (Side Effect)
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib